BI 54903/tiotropium bromide

Drug Profile

BI 54903/tiotropium bromide

Alternative Names: Tiotropium bromide/BI 54903

Latest Information Update: 17 Mar 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiasthmatics; Antibronchitics; Small molecules; Tropanes
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Asthma; Respiratory tract disorders

Most Recent Events

  • 16 Mar 2017 Discontinued - Phase-I for Respiratory tract disorders (In volunteers) in Germany before March 2017 (Inhalation)
  • 16 Mar 2017 Discontinued - Phase-II for Asthma in Slovakia before March 2017 (Inhalation)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Respiratory-tract-disorders(In volunteers) in Germany (Inhalation, Powder)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top